Indaptus Therapeutics, Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Indaptus Therapeutics amended its at-the-market (ATM) offering agreement with H.C. Wainwright Co., LLC on August 28, 2026, replacing the June 1, 2022 agreement. The new agreement increases the maximum aggregate offering price from prior limits to $100,000,000 of common stock ($0.01 par value). H.C. Wainwright acts as sales agent with a 3.0% broker fee on sales and can also purchase shares as principal under separate Terms Agreements. The registration statement (Form S-3, File 333-289573) was filed August 13, 2025 and declared effective August 20, 2025. Prospectus supplement filed August 31, 2026.
Why this rating
ATM offering provides $100M liquidity capacity—17x company's $5.8M market cap, highly material for cash-strapped biotech. Dilutive to shareholders but typical for development-stage firms needing runway. No imminent sales announced; agreement is enabling framework.
Price action (we called it neutral)
at our read · unknown $1.15 | +10 min · unknown $1.15 ▲ 0.00% | +30 min · unknown $1.15 ▲ 0.00% | +1 hr · unknown $1.15 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.